Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
US Department of Justice
Merck
Accenture
Express Scripts
Moodys
Teva
Baxter
Boehringer Ingelheim

Generated: August 19, 2018

DrugPatentWatch Database Preview

Tavaborole - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic sources for tavaborole and what is the scope of tavaborole patent protection?

Tavaborole is the generic ingredient in one branded drug marketed by Anacor Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tavaborole has sixty-nine patent family members in twenty countries.

There are six drug master file entries for tavaborole. One supplier is listed for this compound.

Pharmacology for tavaborole
Ingredient-typeBoron Compounds
Drug ClassOxaborole Antifungal
Mechanism of ActionProtein Synthesis Inhibitors
Synonyms for tavaborole
1,3-dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole
174671-46-6
2,1-Benzoxaborole, 5-fluoro-1,3-dihydro-1-hydroxy-
3338AH
5-fluoro-1-hydroxy-3H-2,1-benzoxaborole
5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole
5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol
5-fluoro-2,1-benzoxaborol-1(3H)-ol
5-Fluoro-3H-benzo[c][1,2)oxaborol-1-ol
5-fluoro-3H-benzo[c][1,2]oxaborol-1-ol
5-FLUOROBENZO[C][1,2]OXABOROL-1(3H)-OL
AK163946
AKOS006303927
AN 2690
AN-2690
AN-2690(Tavaborole)
AN-2690)
AN2690
BDBM50370987
C7H6BFO2
CHEBI:77942
CHEMBL443052
CS-1058
CTK8H2675
D05VGL
D10169
DB09041
DTXSID00169888
EX-A1086
FT-0697827
Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
Fungal leucyl-tRNA synthetase inhibitor (onychomycosis), Merck & Co/Anacor
HSDB 8342
HY-10980
K124A4EUQ3
KB-74687
Kerydin
Kerydin (TN)
KS-00000SPV
LFQDNHWZDQTITF-UHFFFAOYSA-N
MB08883
MFCD10699483
MolPort-027-845-281
NCGC00264110-01
SCH-900340
SCHEMBL500016
ST24044751
Tavaborole (USAN)
Tavaborole [USAN:INN]
Topical antifungal (onychomycosis), Merck & Co
Trichophyton-targeting antifungal (onychomycosis), Anacor Pharmaceuticals/Schering-Plough
Trichophyton-targeting antifungal (onychomycosis), Merck & Co
UNII-K124A4EUQ3
W-5454
X3699
Z1739256284
ZINC169990691

US Patents and Regulatory Information for tavaborole

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Anacor Pharms Inc KERYDIN tavaborole SOLUTION;TOPICAL 204427-001 Jul 7, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for tavaborole

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,767,657 Boron-containing small molecules ➤ Try a Free Trial
8,039,451 Boron-containing small molecules ➤ Try a Free Trial
8,115,026 Boron-containing small molecules ➤ Try a Free Trial
8,440,642 Boron-containing small molecules ➤ Try a Free Trial
8,722,917 Boron-containing small molecules ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Harvard Business School
Deloitte
Fish and Richardson
Argus Health
Moodys
AstraZeneca
US Department of Justice
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.